Dies ist ein
Mega Burner 
http://www.finanznachrichten.de/nachrichten-2012-11/25047300…
Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF
Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus
BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing
new treatments and diagnostics for Parkinson's disease and
Traumatic Brain Injury centred on its proprietary anti-apoptosis
therapeutic protein MANF, today announced that it intends to pursue
the identification of one or multiple therapeutic indications for
its lead therapeutic candidate MANF that could lead to the therapy
receiving orphan drug designation(s) with the Food and Drug
Administration (FDA). The strategy is centred on exploiting MANF's
unique mechanism of action related to facilitating proper protein
folding and processing in the endoplasmic reticulum in order to
identify rare and/or ultra-rare diseases where MANF treatment may
play a significant role in improving patient outcomes in disease
states where no other treatment options are currently available.